Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 14, 2015, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $78.54 to $2,171,047.50.

Highlighted Stocks Traded by Insiders:

Colfax (CFX) - FREE Research Report

Kiefaber Clay, who is ESAB Global CEO & EVP - Colfax at Colfax, sold 9,208 shares at $47.54 on Jan. 14, 2015. Following this transaction, the ESAB Global CEO & EVP - Colfax owned 108,823 shares meaning that the stake was reduced by 7.8% with the 9,208-share transaction.

The shares most recently traded at $45.93, down $1.61, or 3.51% since the insider transaction. Historical insider transactions for Colfax go as follows:

  • 4-Week # shares bought: 1,222
  • 4-Week # shares sold: 1,380
  • 12-Week # shares bought: 1,222
  • 12-Week # shares sold: 1,380
  • 24-Week # shares bought: 8,022
  • 24-Week # shares sold: 3,406

The average volume for Colfax has been 1.0 million shares per day over the past 30 days. Colfax has a market cap of $5.8 billion and is part of the industrial goods sector and industrial industry. Shares are down 10.34% year-to-date as of the close of trading on Wednesday.

Colfax Corporation, a diversified industrial manufacturing and engineering company, provides gas-and fluid-handling and fabrication technology products and services to commercial and governmental customers worldwide. The company has a P/E ratio of 17.5. Currently, there are 4 analysts who rate Colfax a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFX - FREE

TheStreet Quant Ratings rates Colfax as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Colfax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Arrowhead Research (ARWR) - FREE Research Report

Ferrari Mauro, who is Director at Arrowhead Research, bought 2,300 shares at $6.44 on Jan. 14, 2015. Following this transaction, the Director owned 4,251 shares meaning that the stake was boosted by 117.89% with the 2,300-share transaction.

The shares most recently traded at $6.75, up $0.31, or 4.62% since the insider transaction. Historical insider transactions for Arrowhead Research go as follows:

  • 4-Week # shares bought: 16,000
  • 12-Week # shares bought: 16,000
  • 24-Week # shares bought: 16,000

The average volume for Arrowhead Research has been 2.8 million shares per day over the past 30 days. Arrowhead Research has a market cap of $345.6 million and is part of the health care sector and drugs industry. Shares are down 9.08% year-to-date as of the close of trading on Wednesday.

Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company has a P/E ratio of 5.1. Currently, there are 4 analysts who rate Arrowhead Research a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARWR - FREE

TheStreet Quant Ratings rates Arrowhead Research as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Arrowhead Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Foundation Medicine (FMI) - FREE Research Report

Pellini Michael J, who is President & CEO at Foundation Medicine, sold 22,500 shares at $51.07 on Jan. 14, 2015. Following this transaction, the President & CEO owned 437,500 shares meaning that the stake was reduced by 4.89% with the 22,500-share transaction.

Miller Vincent A., who is Chief Medical Officer at Foundation Medicine, sold 2,000 shares at $53.03 on Jan. 14, 2015. Following this transaction, the Chief Medical Officer owned 99,062 shares meaning that the stake was reduced by 1.98% with the 2,000-share transaction.

Hesslein Robert W., who is SVP and General Counsel at Foundation Medicine, sold 7,000 shares at $52.11 on Jan. 14, 2015. Following this transaction, the SVP and General Counsel owned 60,125 shares meaning that the stake was reduced by 10.43% with the 7,000-share transaction.

The shares most recently traded at $48.41, down $3.70, or 7.65% since the insider transaction. Historical insider transactions for Foundation Medicine go as follows:

  • 4-Week # shares sold: 16,921
  • 12-Week # shares sold: 29,421
  • 24-Week # shares sold: 58,912

The average volume for Foundation Medicine has been 425,600 shares per day over the past 30 days. Foundation Medicine has a market cap of $1.4 billion and is part of the health care sector and health services industry. Shares are up 123.94% year-to-date as of the close of trading on Wednesday.

Foundation Medicine, Inc. provides various molecular information products in the United States. The company has a P/E ratio of 13.9. Currently, there are 4 analysts who rate Foundation Medicine a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMI - FREE

TheStreet Quant Ratings rates Foundation Medicine as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Foundation Medicine Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null